Thrive Earlier Detection Corp. Revenue and Competitors

Boston, MA USA

Location

$367M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Thrive Earlier Detection Corp.'s estimated annual revenue is currently $34.1M per year.(i)
  • Thrive Earlier Detection Corp.'s estimated revenue per employee is $193,750
  • Thrive Earlier Detection Corp.'s total funding is $367M.

Employee Data

  • Thrive Earlier Detection Corp. has 176 Employees.(i)
  • Thrive Earlier Detection Corp. grew their employee count by -26% last year.

Thrive Earlier Detection Corp.'s People

NameTitleEmail/Phone
1
Co-Founder and Chief Innovation Partner,Reveal Email/Phone
2
CFOReveal Email/Phone
3
CEOReveal Email/Phone
4
VP, Biostatistics and InformaticsReveal Email/Phone
5
Head Research And DevelopmentReveal Email/Phone
6
VP Laboratory OperationsReveal Email/Phone
7
EVP & Head Product SolutionsReveal Email/Phone
8
Director Payer RelationsReveal Email/Phone
9
Senior Director, R&DReveal Email/Phone
10
Director Product Strategy & Patient ExperienceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Thrive Earlier Detection Corp.?

A cancer diagnosis is something no one wants to hear. Today, it is often detected late, once it has spread and treatment options are often limited. But cancer is curable if caught in the earlier stages. At Thrive Earlier Detection, our goal is to transform this outlook: to catch cancer earlier, when it can be more effectively treated. We are developing CancerSEEK, a blood-based test that is designed to be affordable and utilized as part of routine medical care to detect multiple types of cancer at earlier stages. Our approach goes beyond a cancer diagnosis. We are developing a platform that will serve as a resource to help patients and their families maneuver the often confusing and overwhelming path that follows a cancer diagnosis.

keywords:N/A

$367M

Total Funding

176

Number of Employees

$34.1M

Revenue (est)

-26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Thrive Earlier Detection Corp. News

2022-04-20 - Exact Sciences : announces first quarter 2022 results - Form 8-K

•Total first quarter revenue of $487M, including Screening revenue of ... which relates to our acquisition of Thrive Earlier Detection Corp.

2022-04-20 - Exact Sciences (EXAS) Q1 2022 Earnings Call Transcript

The Exact Sciences' mission is to eradicate cancer by making earlier detection a routine part of medical care.

2022-04-20 - Exact Sciences Announces First Quarter 2022 Results

MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. ... of which relates to our acquisition of Thrive Earlier Detection Corp.

2020-07-30 - Thrive Earlier Detection snags $257M for biopsy testing

Thrive Earlier Detection has raised $257 million in a Series B led by Casdin Capital and Section 32. Other investors including Bain Capital, Janus Henderson, T. Rowe Price and Lux Capital also supported the round. The funds will help advance the company's development of a liquid biopsy test desi ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$52.6M177N/AN/A
#2
$28.2M1775%N/A
#3
$32.1M17712%N/A
#4
$34.5M17829%$338M
#5
$47.6M1781%N/A